Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187450 | 0.91 | GPR119 (0.47) | GPR119USP30PRMT5YAP1STS | |
| SCHEMBL6983268 | 0.84 | GPR119 (0.49) | GPR119YAP1STSPTPRBPTPN11 | |
| SCHEMBL6378254 | 0.83 | PTPRB (0.53) | GPR119YAP1STSPTPRBPTPN11 | |
| SCHEMBL15531502 | 0.82 | GPR119 (0.44) | GPR119USP30PRMT5YAP1STS | |
| SCHEMBL76105 | 0.81 | YAP1 (0.60) | GPR119USP30PRMT5YAP1STS | |
| SCHEMBL15530172 | 0.80 | GPR119 (0.45) | GPR119USP30PRMT5YAP1STS | |
| SCHEMBL5868120 | 0.80 | KMT2A (0.52) | GPR119YAP1STSPTPRBPTPN11 | |
| SCHEMBL4842101 | 0.80 | MEN1 (0.46) | GPR119STSPTPRBPTPN11MEN1 | |
| SCHEMBL7220781 | 0.79 | GPR119 (0.45) | GPR119PRMT5YAP1STS | |
| SCHEMBL6192978 | 0.79 | GPR119 (0.51) | GPR119YAP1STSHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | GPR119 2900/4885USP30 4217/4885PRMT5 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.